Skip to main content

Adicet Bio, Inc.

ACET
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001720580

No open-market purchases or sales by Adicet Bio, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $52.8M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Adicet Bio, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of ACET: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders5649−7
Shares55.9M51.6M−4.25M (−7.6%)
Value$42.0M$31.5M−$10.6M (−25.1%)

New holders (10)

Institutions that held Adicet Bio, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to ACET in Q2 2025
InstitutionSharesValue% of portfolio
Schonfeld Strategic Advisors LLC1,880,095$1.15M0.01%
Luminus Management LLC289,935$176.9K0.05%
Barclays PLC150,000$91.5K0.00%
Abacus Planning Group, Inc.36,764$22.4K0.00%
XTX Topco Ltd23,580$14.4K0.00%
Landscape Capital Management, L.L.C.17,846$10.9K0.00%
Raymond James Financial Inc3,752$2.29K0.00%
Toth Financial Advisory Corp1,600$9760.00%
Riggs Asset Managment Co. Inc.1,122$6850.00%
Royal Bank of Canada88$00.00%

Sold out (17)

Institutions that held Adicet Bio, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.